Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):629–638. doi: 10.1038/sj.bjc.6690404

The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects

G A P Hospers 1, E A Eisenhauer 2, E G E de Vries 1
PMCID: PMC2362304  PMID: 10360638

Abstract

Radio- and chemotherapy for the treatment of malignancies are often associated with significant toxicity. One approach to reduce the toxicity is the concomitant treatment with chemoprotective agents. This article reviews two sulfhydryl compounds, namely the agent WR-2721 (amifostine), a compound recently registered for use in human in many countries, and the natural occurring compound glutathione (GSH). GSH is not registered as a chemoprotective agent. WR-2721 is an aminothiol prodrug and has to be converted to the active compound WR-1065 by membrane-bound alkaline phosphatase. WR-1065 and GSH both act as naturally occurring thiols. No protective effect on the tumour has been found when these compounds are administered intravenously. There is even in vitro evidence for an increased anti-tumour effect with mafosfamide after pretreatment with WR-2721, and in vivo after treatment with carboplatin and paclitaxel. Randomized clinical studies have shown that WR-2721 and GSH decrease cisplatin-induced nephrotoxicity and that WR-2721 reduces radiation radiotherapy-induced toxicity. Side-effects associated with WR-2721 are nausea, vomiting and hypotension, GSH has no side-effects. An exact role of WR-2721 and GSH as chemoprotectors is not yet completely clear. Future studies should examine the protective effect of these drugs on mucositis, cardiac toxicity, neuro- and ototoxicity, the development of secondary neoplasms and their effect on quality of life. © 1999 Cancer Research Campaign

Keywords: WR-2721, glutathione, chemoprotection

Full Text

The Full Text of this article is available as a PDF (146.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aebi S., Assereto R., Lauterburg B. H. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest. 1991 Feb;21(1):103–110. doi: 10.1111/j.1365-2362.1991.tb01366.x. [DOI] [PubMed] [Google Scholar]
  2. Alberts D. S., Liu P. Y., Hannigan E. V., O'Toole R., Williams S. D., Young J. A., Franklin E. W., Clarke-Pearson D. L., Malviya V. K., DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996 Dec 26;335(26):1950–1955. doi: 10.1056/NEJM199612263352603. [DOI] [PubMed] [Google Scholar]
  3. Alberts D. S., Noel J. K. Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs. 1995 Jun;6(3):369–383. doi: 10.1097/00001813-199506000-00003. [DOI] [PubMed] [Google Scholar]
  4. Ben-Josef E., Mesina J., Shaw L. M., Bonner H. S., Shamsa F., Porter A. T. Topical application of WR-2721 achieves high concentrations in the rectal wall. Radiat Res. 1995 Jul;143(1):107–110. [PubMed] [Google Scholar]
  5. Betticher D. C., Anderson H., Ranson M., Meely K., Oster W., Thatcher N. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study. Br J Cancer. 1995 Dec;72(6):1551–1555. doi: 10.1038/bjc.1995.546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Budd G. T. Amifostine and chemotherapy-related thrombocytopenia. Semin Oncol. 1996 Aug;23(4 Suppl 8):49–52. [PubMed] [Google Scholar]
  7. Büntzel J., Küttner K., Fröhlich D., Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998 May;9(5):505–509. doi: 10.1023/a:1008282412670. [DOI] [PubMed] [Google Scholar]
  8. Calabro-Jones P. M., Aguilera J. A., Ward J. F., Smoluk G. D., Fahey R. C. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res. 1988 Jul 1;48(13):3634–3640. [PubMed] [Google Scholar]
  9. Calabro-Jones P. M., Fahey R. C., Smoluk G. D., Ward J. F. Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol Relat Stud Phys Chem Med. 1985 Jan;47(1):23–27. doi: 10.1080/09553008514550041. [DOI] [PubMed] [Google Scholar]
  10. Capizzi R. L., Oster W. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences. Eur J Cancer. 1995;31A Suppl 1:S8–13. doi: 10.1016/0959-8049(95)00144-8. [DOI] [PubMed] [Google Scholar]
  11. Delaney J. P., Bonsack M. E., Felemovicius I. Radioprotection of the rat small intestine with topical WR-2721. Cancer. 1994 Oct 15;74(8):2379–2384. doi: 10.1002/1097-0142(19941015)74:8<2379::aid-cncr2820740825>3.0.co;2-j. [DOI] [PubMed] [Google Scholar]
  12. Di Re F., Bohm S., Oriana S., Spatti G. B., Pirovano C., Tedeschi M., Zunino F. High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann Oncol. 1993 Jan;4(1):55–61. doi: 10.1093/oxfordjournals.annonc.a058362. [DOI] [PubMed] [Google Scholar]
  13. Di Re F., Bohm S., Oriana S., Spatti G. B., Zunino F. Efficacy and safety of high-dose cisplatin and cyclophosphamide with glutathione protection in the treatment of bulky advanced epithelial ovarian cancer. Cancer Chemother Pharmacol. 1990;25(5):355–360. doi: 10.1007/BF00686237. [DOI] [PubMed] [Google Scholar]
  14. Dorr R. T. Cytoprotective agents for anthracyclines. Semin Oncol. 1996 Aug;23(4 Suppl 8):23–34. [PubMed] [Google Scholar]
  15. Douay L., Hu C., Giarratana M. C., Bouchet S., Conlon J., Capizzi R. L., Gorin N. C. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging. Blood. 1995 Oct 1;86(7):2849–2855. [PubMed] [Google Scholar]
  16. Dunn T. A., Schmoll H. J., Grünwald V., Bokemeyer C., Casper J. Amifostine does not alter the antitumor activity of cisplatin in a pre-clinical model of testicular cancer. Anticancer Drugs. 1996 Sep;7(7):795–799. doi: 10.1097/00001813-199609000-00013. [DOI] [PubMed] [Google Scholar]
  17. Ercan M. T., Aras T., Aktaş A., Kaya S., Bekdik C. F. Accumulation of 99mTc-glutathione in head and neck tumors. Nuklearmedizin. 1994 Oct;33(5):224–228. [PubMed] [Google Scholar]
  18. Glick J. H., Glover D., Weiler C., Norfleet L., Yuhas J., Kligerman M. M. Phase I controlled trials of WR-2721 and cyclophosphamide. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1777–1780. doi: 10.1016/0360-3016(84)90548-0. [DOI] [PubMed] [Google Scholar]
  19. Glover D., Glick J. H., Weiler C., Fox K., Turrisi A., Kligerman M. M. Phase I/II trials of WR-2721 and cis-platinum. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1509–1512. doi: 10.1016/0360-3016(86)90205-1. [DOI] [PubMed] [Google Scholar]
  20. Grdina D. J., Kataoka Y., Basic I., Perrin J. The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation. Carcinogenesis. 1992 May;13(5):811–814. doi: 10.1093/carcin/13.5.811. [DOI] [PubMed] [Google Scholar]
  21. Grdina D. J., Shigematsu N., Dale P., Newton G. L., Aguilera J. A., Fahey R. C. Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action. Carcinogenesis. 1995 Apr;16(4):767–774. doi: 10.1093/carcin/16.4.767. [DOI] [PubMed] [Google Scholar]
  22. Gyenes G., Fornander T., Carlens P., Rutqvist L. E. Morbidity of ischemic heart disease in early breast cancer 15-20 years after adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 1994 Mar 30;28(5):1235–1241. doi: 10.1016/0360-3016(94)90500-2. [DOI] [PubMed] [Google Scholar]
  23. Hamers F. P., Brakkee J. H., Cavalletti E., Tedeschi M., Marmonti L., Pezzoni G., Neijt J. P., Gispen W. H. Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res. 1993 Feb 1;53(3):544–549. [PubMed] [Google Scholar]
  24. Hill C. K., Nagy B., Peraino C., Grdina D. J. 2-[(Aminopropyl)amino]ethanethiol (WR1065) is anti-neoplastic and anti-mutagenic when given during 60Co gamma-ray irradiation. Carcinogenesis. 1986 Apr;7(4):665–668. doi: 10.1093/carcin/7.4.665. [DOI] [PubMed] [Google Scholar]
  25. Kaltenbach J. A., Church M. W., Blakley B. W., McCaslin D. L., Burgio D. L. Comparison of five agents in protecting the cochlea against the ototoxic effects of cisplatin in the hamster. Otolaryngol Head Neck Surg. 1997 Nov;117(5):493–500. doi: 10.1016/S0194-59989770020-2. [DOI] [PubMed] [Google Scholar]
  26. Kataoka Y., Basic I., Perrin J., Grdina D. J. Antimutagenic effects of radioprotector WR-2721 against fission-spectrum neurons and 60Co gamma-rays in mice. Int J Radiat Biol. 1992 Mar;61(3):387–392. doi: 10.1080/09553009214551081. [DOI] [PubMed] [Google Scholar]
  27. Kemp G., Rose P., Lurain J., Berman M., Manetta A., Roullet B., Homesley H., Belpomme D., Glick J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996 Jul;14(7):2101–2112. doi: 10.1200/JCO.1996.14.7.2101. [DOI] [PubMed] [Google Scholar]
  28. Korst A. E., Eeltink C. M., Vermorken J. B., van der Vijgh W. J. Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer. 1997 Aug;33(9):1425–1429. doi: 10.1016/s0959-8049(97)00138-x. [DOI] [PubMed] [Google Scholar]
  29. Leone R., Fracasso M. E., Soresi E., Cimino G., Tedeschi M., Castoldi D., Monzani V., Colombi L., Usari T., Bernareggi A. Influence of glutathione administration on the disposition of free and total platinum in patients after administration of cisplatin. Cancer Chemother Pharmacol. 1992;29(5):385–390. doi: 10.1007/BF00686008. [DOI] [PubMed] [Google Scholar]
  30. Lipshultz S. E., Colan S. D., Gelber R. D., Perez-Atayde A. R., Sallan S. E., Sanders S. P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991 Mar 21;324(12):808–815. doi: 10.1056/NEJM199103213241205. [DOI] [PubMed] [Google Scholar]
  31. List A. F., Brasfield F., Heaton R., Glinsmann-Gibson B., Crook L., Taetle R., Capizzi R. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood. 1997 Nov 1;90(9):3364–3369. [PubMed] [Google Scholar]
  32. Liu S. C., Murley J. S., Woloschak G., Grdina D. J. Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine. Carcinogenesis. 1997 Dec;18(12):2457–2459. doi: 10.1093/carcin/18.12.2457. [DOI] [PubMed] [Google Scholar]
  33. Liu T., Liu Y., He S., Zhang Z., Kligerman M. M. Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer. 1992 Jun 1;69(11):2820–2825. doi: 10.1002/1097-0142(19920601)69:11<2820::aid-cncr2820691130>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  34. Locatelli M. C., D'Antona A., Labianca R., Vinci M., Tedeschi M., Carcione R., Corbo A., Venturino P., Luporini G. A phase II study of combination chemotherapy in advanced ovarian carcinoma with cisplatin and cyclophosphamide plus reduced glutathione as potential protective agent against cisplatin toxicity. Tumori. 1993 Feb 28;79(1):37–39. doi: 10.1177/030089169307900108. [DOI] [PubMed] [Google Scholar]
  35. Mangold D. J., Miller M. A., Huelle B. K., Sanchez-Barona D. O., Swynnerton N. F., Fleckenstein L., Ludden T. M. Disposition of the radioprotector ethiofos in the rhesus monkey. Influence of route of administration. Drug Metab Dispos. 1989 May-Jun;17(3):304–310. [PubMed] [Google Scholar]
  36. McGuire W. P., Hoskins W. J., Brady M. F., Kucera P. R., Partridge E. E., Look K. Y., Clarke-Pearson D. L., Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996 Jan 4;334(1):1–6. doi: 10.1056/NEJM199601043340101. [DOI] [PubMed] [Google Scholar]
  37. Meister A. Selective modification of glutathione metabolism. Science. 1983 Apr 29;220(4596):472–477. doi: 10.1126/science.6836290. [DOI] [PubMed] [Google Scholar]
  38. Milas L., Hunter N., Stephens L. C., Peters L. J. Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1984 Dec;44(12 Pt 1):5567–5569. [PubMed] [Google Scholar]
  39. Millar J. L., McElwain T. J., Clutterbuck R. D., Wist E. A. The modification of melphalan toxicity in tumor bearing mice by s-2-(3-aminopropylamino)- ethylphosphorothioic acid (WR 2721). Am J Clin Oncol. 1982 Jun;5(3):321–328. doi: 10.1097/00000421-198206000-00015. [DOI] [PubMed] [Google Scholar]
  40. Mollman J. E., Glover D. J., Hogan W. M., Furman R. E. Cisplatin neuropathy. Risk factors, prognosis, and protection by WR-2721. Cancer. 1988 Jun 1;61(11):2192–2195. doi: 10.1002/1097-0142(19880601)61:11<2192::aid-cncr2820611110>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  41. Montana G. S., Anscher M. S., Mansbach C. M., 2nd, Daly N., Delannes M., Carke-Pearson D., Gaydica E. F. Topical application of WR-2721 to prevent radiation-induced proctosigmoiditis. A phase I/II trial. Cancer. 1992 Jun 1;69(11):2826–2830. doi: 10.1002/1097-0142(19920601)69:11<2826::aid-cncr2820691131>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  42. Mori T., Nikaido O., Sugahara T. Dephosphorylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1529–1531. doi: 10.1016/0360-3016(84)90496-6. [DOI] [PubMed] [Google Scholar]
  43. Murley J. S., Constantinou A., Kamath N. S., Grdina D. J. WR-1065, an active metabolite of the cytoprotector amifostine, affects phosphorylation of topoisomerase II alpha leading to changes in enzyme activity and cell cycle progression in CHO AA8 cells. Cell Prolif. 1997 Jun-Jul;30(6-7):283–294. doi: 10.1046/j.1365-2184.1997.00092.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Murley J. S., Grdina D. J. The effects of cycloheximide and WR-1065 on radiation-induced repair processes: a mechanism for chemoprevention. Carcinogenesis. 1995 Nov;16(11):2699–2705. doi: 10.1093/carcin/16.11.2699. [DOI] [PubMed] [Google Scholar]
  45. Nagy B., Dale P. J., Grdina D. J. Protection against cis-diamminedichloroplatinum cytotoxicity and mutagenicity in V79 cells by 2-[(aminopropyl)amino]ethanethiol. Cancer Res. 1986 Mar;46(3):1132–1135. [PubMed] [Google Scholar]
  46. Nagy B., Grdina D. J. Protective effects of 2-[(aminopropyl)amino] ethanethiol against bleomycin and nitrogen mustard-induced mutagenicity in V79 cells. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1475–1478. doi: 10.1016/0360-3016(86)90197-5. [DOI] [PubMed] [Google Scholar]
  47. Nooijen P. T., Westphal J. R., Eggermont A. M., Schalkwijk C., Max R., de Waal R. M., Ruiter D. J. Endothelial P-selectin expression is reduced in advanced primary melanoma and melanoma metastasis. Am J Pathol. 1998 Mar;152(3):679–682. [PMC free article] [PubMed] [Google Scholar]
  48. Parnis F. X., Coleman R. E., Harper P. G., Pickering D., Topham C., Whittington J. R., Tedeschi M. A randomised double-blind placebo controlled clinical trial assessing the tolerability and efficacy of glutathione as an adjuvant to escalating doses of cisplatin in the treatment of advanced ovarian cancer. Eur J Cancer. 1995 Sep;31A(10):1721–1721. doi: 10.1016/0959-8049(95)00310-f. [DOI] [PubMed] [Google Scholar]
  49. Poplin E. A., LoRusso P., Lokich J. J., Gullo J. J., Leming P. D., Schulz J. J., Veach S. R., McCulloch W., Baker L., Schein P. Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 1994;33(5):415–419. doi: 10.1007/BF00686271. [DOI] [PubMed] [Google Scholar]
  50. Romero F. J., Segura-Aguilar J., Monsalve E., Hermenegildo C., Nies E., Puertas F. J., Romá J. Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve. Neurotoxicol Teratol. 1990 Nov-Dec;12(6):603–605. doi: 10.1016/0892-0362(90)90069-o. [DOI] [PubMed] [Google Scholar]
  51. Rubin J. S., Wadler S., Beitler J. J., Haynes H., Rozenblit A., McGill F., Goldberg G., Runowicz C. Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma. J Laryngol Otol. 1995 Aug;109(8):744–747. doi: 10.1017/s0022215100131202. [DOI] [PubMed] [Google Scholar]
  52. Sajjan A. R., Hinchigeri S. B., Datta K. S. Multiple forms of gamma-glutamyl transpeptidase in human submandibular gland. Clin Chim Acta. 1991 Mar 15;197(2):133–139. doi: 10.1016/0009-8981(91)90275-h. [DOI] [PubMed] [Google Scholar]
  53. Schiller J. H., Storer B., Berlin J., Wittenkeller J., Larson M., Pharo L., Larson M., Berry W. Amifostine, cisplatin, and vinblastine in metastatic non-small-cell lung cancer: a report of high response rates and prolonged survival. J Clin Oncol. 1996 Jun;14(6):1913–1921. doi: 10.1200/JCO.1996.14.6.1913. [DOI] [PubMed] [Google Scholar]
  54. Schwint A. E., Collet A. M., Mendez A. E., Cabrini R. L., Itoiz M. E. The first normal oral mucosa epithelium in which gamma-glutamyl transpeptidase activity has been detected. Histochem J. 1992 Dec;24(12):964–968. doi: 10.1007/BF01046502. [DOI] [PubMed] [Google Scholar]
  55. Shapiro C. L., Henderson I. C. Late cardiac effects of adjuvant therapy: too soon to tell? Ann Oncol. 1994 Mar;5(3):196–198. doi: 10.1093/oxfordjournals.annonc.a058792. [DOI] [PubMed] [Google Scholar]
  56. Shaw L. M., Turrisi A. T., Glover D. J., Bonner H. S., Norfleet A. L., Weiler C., Kligerman M. M. Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Phys. 1986 Aug;12(8):1501–1504. doi: 10.1016/0360-3016(86)90203-8. [DOI] [PubMed] [Google Scholar]
  57. Shpall E. J., Stemmer S. M., Hami L., Franklin W. A., Shaw L., Bonner H. S., Bearman S. I., Peters W. P., Bast R. C., Jr, McCulloch W. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994 Jun 1;83(11):3132–3137. [PubMed] [Google Scholar]
  58. Smoluk G. D., Fahey R. C., Calabro-Jones P. M., Aguilera J. A., Ward J. F. Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection. Cancer Res. 1988 Jul 1;48(13):3641–3647. [PubMed] [Google Scholar]
  59. Smyth J. F., Bowman A., Perren T., Wilkinson P., Prescott R. J., Quinn K. J., Tedeschi M. Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann Oncol. 1997 Jun;8(6):569–573. doi: 10.1023/a:1008211226339. [DOI] [PubMed] [Google Scholar]
  60. Swain S. M., Whaley F. S., Gerber M. C., Weisberg S., York M., Spicer D., Jones S. E., Wadler S., Desai A., Vogel C. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997 Apr;15(4):1318–1332. doi: 10.1200/JCO.1997.15.4.1318. [DOI] [PubMed] [Google Scholar]
  61. Taylor C. W., Wang L. M., List A. F., Fernandes D., Paine-Murrieta G. D., Johnson C. S., Capizzi R. L. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained. Eur J Cancer. 1997 Sep;33(10):1693–1698. doi: 10.1016/s0959-8049(97)00221-9. [DOI] [PubMed] [Google Scholar]
  62. Thompson D. C., Wyrick S. D., Holbrook D. J., Chaney S. G. HPLC and 31P NMR characterization of the reaction between antitumor platinum agents and the phosphorothioate chemoprotective agent S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). Biochem Pharmacol. 1995 Oct 26;50(9):1413–1419. doi: 10.1016/0006-2952(96)84545-x. [DOI] [PubMed] [Google Scholar]
  63. Treskes M., Boven E., van de Loosdrecht A. A., Wijffels J. F., Cloos J., Peters G. J., Pinedo H. M., van der Vijgh W. J. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice. Eur J Cancer. 1994;30A(2):183–187. doi: 10.1016/0959-8049(94)90084-1. [DOI] [PubMed] [Google Scholar]
  64. Treskes M., Holwerda U., Klein I., Pinedo H. M., van der Vijgh W. J. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol. 1991 Nov 6;42(11):2125–2130. doi: 10.1016/0006-2952(91)90347-8. [DOI] [PubMed] [Google Scholar]
  65. Utley J. F., Marlowe C., Waddell W. J. Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2. Radiat Res. 1976 Nov;68(2):284–291. [PubMed] [Google Scholar]
  66. Valeriote F., Tolen S. Protection and potentiation of nitrogen mustard cytotoxicity by WR-2721. Cancer Res. 1982 Nov;42(11):4330–4331. [PubMed] [Google Scholar]
  67. Washburn L. C., Rafter J. J., Hayes R. L. Prediction of the effective radioprotective dose of WR-2721 in humans through an interspecies tissue distribution study. Radiat Res. 1976 Apr;66(1):100–105. [PubMed] [Google Scholar]
  68. Wasserman T. H., Phillips T. L., Ross G., Kane L. J. Differential protection against cytotoxic chemotherapeutic effects on bone marrow CFUs by Wr-2721. Cancer Clin Trials. 1981;4(1):3–6. [PubMed] [Google Scholar]
  69. Weiss J. F. Pharmacologic approaches to protection against radiation-induced lethality and other damage. Environ Health Perspect. 1997 Dec;105 (Suppl 6):1473–1478. doi: 10.1289/ehp.97105s61473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Woolley P. V., 3rd, Ayoob M. J., Smith F. P., Dritschilo A. Clinical trial of the effect of S-2-(3-aminopropylamino)-ethylphosphorothioic acid (WR-2721) (NSC 296961) on the toxicity of cyclophosphamide. J Clin Oncol. 1983 Mar;1(3):198–203. doi: 10.1200/JCO.1983.1.3.198. [DOI] [PubMed] [Google Scholar]
  71. Yuhas J. M. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. Cancer Res. 1980 May;40(5):1519–1524. [PubMed] [Google Scholar]
  72. Zunino F., Pratesi G., Micheloni A., Cavalletti E., Sala F., Tofanetti O. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interact. 1989;70(1-2):89–101. doi: 10.1016/0009-2797(89)90065-3. [DOI] [PubMed] [Google Scholar]
  73. de Wit R., Stoter G., Sleijfer D. T., Kaye S. B., de Mulder P. H., ten Bokkel Huinink W. W., Spaander P. J., de Pauw M., Sylvester R. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995 Jun;71(6):1311–1314. doi: 10.1038/bjc.1995.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. van der Vijgh W. J., Korst A. E. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo. Eur J Cancer. 1996;32A Suppl 4:S26–S30. doi: 10.1016/s0959-8049(96)00332-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES